Download
s00345-021-03889-x.pdf 812,65KB
WeightNameValue
1000 Titel
  • Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer
1000 Autor/in
  1. Dieckmann, K. P. |
  2. Ruckes, C. |
  3. Schmelz, H. U. |
  4. Dotzauer, R. |
  5. Hiester, A. |
  6. Bolenz, C. |
  7. Loosen, S. H. |
  8. Heidenreich, A. |
  9. Pfister, D. |
  10. Haferkamp, A. |
  11. Brandt, Maximilian Peter |
  12. Ruf, C. |
  13. Syring, I. |
  14. Nestler, T. |
  15. Albers, P. |
  16. Nettersheim, D. |
  17. Zengerling, F. |
  18. Paffenholz, P. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-12-02
1000 Erschienen in
1000 Quellenangabe
  • 40(2):327-334
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00345-021-03889-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921055/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Clinical stage I (CSI) testicular germ cell tumors (TGCT) represents disease confined to the testis without metastasis and CSIS is defined as persistently elevated tumor markers (TM) after orchiectomy, indicating subclinical metastatic disease. This study aims at assessing clinical characteristics and oncological outcome in CSIS.!##!Methods!#!Data from five tertiary referring centers in Germany were screened. We defined correct classification of CSIS according to EAU guidelines. TM levels, treatment and relapse-free survival were assessed and differences between predefined groups (chemotherapy, correct/incorrect CSIS) were analyzed with Fisher's exact and Chi-square test.!##!Results!#!Out of 2616 TGCT patients, 43 (1.6%) were CSIS. Thereof, 27 were correctly classified (cCSIS, 1.03%) and 16 incorrectly classified (iCSIS). TMs that defined cCSIS were in 12 (44.4%), 10 (37%), 3 (11.1%) and 2 (7.4%) patients AFP, ß-HCG, AFP plus ß-HCG and LDH, respectively. In the cCSIS group, six patients were seminoma and 21 non-seminoma. Treatment consisted of active surveillance, carboplatin-mono AUC7 and BEP (bleomycin, etoposide and cisplatin). No difference between cCSIS and iCSIS with respect to applied chemotherapy was found (p = 0.830). 5-year relapse-free survival was 88.9% and three patients (11%) in the cCSIS group relapsed. All underwent salvage treatment (3xBEP) with no documented death.!##!Conclusion!#!Around 1% of all TGCT were classified as cCSIS patients. Identification of cCSIS is of critical importance to avoid disease progression and relapses by adequate treatment. We report a high heterogeneity of treatment patterns, associated with excellent long-term survival irrespective of the initial treatment approach.
1000 Sacherschließung
lokal Topic Paper
lokal Seminoma
lokal Humans [MeSH]
lokal Orchiectomy [MeSH]
lokal Cisplatin [MeSH]
lokal Etoposide/therapeutic use [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Neoplasms, Germ Cell and Embryonal/drug therapy [MeSH]
lokal Neoplasm Staging [MeSH]
lokal Male [MeSH]
lokal Tumor markers
lokal Clinical stage IS
lokal Seminoma/pathology [MeSH]
lokal Testicular Neoplasms/pathology [MeSH]
lokal Chemotherapy
lokal Neoplasm Recurrence, Local/drug therapy [MeSH]
lokal Neoplasm Recurrence, Local/therapy [MeSH]
lokal Non-seminoma
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RGllY2ttYW5uLCBLLiBQLg==|https://frl.publisso.de/adhoc/uri/UnVja2VzLCBDLg==|https://frl.publisso.de/adhoc/uri/U2NobWVseiwgSC4gVS4=|https://frl.publisso.de/adhoc/uri/RG90emF1ZXIsIFIu|https://frl.publisso.de/adhoc/uri/SGllc3RlciwgQS4=|https://frl.publisso.de/adhoc/uri/Qm9sZW56LCBDLg==|https://frl.publisso.de/adhoc/uri/TG9vc2VuLCBTLiBILg==|https://frl.publisso.de/adhoc/uri/SGVpZGVucmVpY2gsIEEu|https://frl.publisso.de/adhoc/uri/UGZpc3RlciwgRC4=|https://frl.publisso.de/adhoc/uri/SGFmZXJrYW1wLCBBLg==|https://frl.publisso.de/adhoc/uri/QnJhbmR0LCBNYXhpbWlsaWFuIFBldGVy|https://frl.publisso.de/adhoc/uri/UnVmLCBDLg==|https://frl.publisso.de/adhoc/uri/U3lyaW5nLCBJLg==|https://frl.publisso.de/adhoc/uri/TmVzdGxlciwgVC4=|https://frl.publisso.de/adhoc/uri/QWxiZXJzLCBQLg==|https://frl.publisso.de/adhoc/uri/TmV0dGVyc2hlaW0sIEQu|https://frl.publisso.de/adhoc/uri/WmVuZ2VybGluZywgRi4=|https://frl.publisso.de/adhoc/uri/UGFmZmVuaG9seiwgUC4=
1000 Hinweis
  • DeepGreen-ID: bf750651055b401190ebc21ff1801bfc ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6447695.rdf
1000 Erstellt am 2023-05-03T16:09:03.652+0200
1000 Erstellt von 322
1000 beschreibt frl:6447695
1000 Zuletzt bearbeitet Fri Oct 20 21:03:08 CEST 2023
1000 Objekt bearb. Fri Oct 20 21:03:08 CEST 2023
1000 Vgl. frl:6447695
1000 Oai Id
  1. oai:frl.publisso.de:frl:6447695 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source